52 results about "Antibiotic combinations" patented technology

Formulation of ectoparasiticidal and antibiotic “compositions into pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eye crusting.

The invention discloses a single-cell probiotic packaging method of thiolated guluronic acid oligosaccharide and a probiotic microcapsule, and relates to the technical field of biological medicines. The packaging method comprises the following steps: mixing a thiolated guluronic acid oligosaccharide solution with a probiotic suspension to form a probiotic-polysaccharide mixed solution; and adding a calcium chloride solution into the probiotic-polysaccharide mixed solution, and stirring to form the single-cell microcapsule encapsulating the probiotics. The packaging method can protect a single strain from being damaged by an external adverse environment to the maximum extent, and the survival rate is increased. Meanwhile, the obtained single-cell microcapsule can improve the digestion of the probiotics, the survival rate of the probiotics under the oxidative stress environment and the antibiotic combination, has high stability, and prolongs the intestinal residence time of the probiotics. An innovative solution is provided for the problems that in the existing medicine field, probiotic preparations cannot improve the gastrointestinal stress resistance of probiotics, and antibiotics lose efficacy when combined.

The invention discloses identification and application of a mycobacterium tuberculosis bacteriophage susceptibility gene, and a gene target which affects mycobacterium bacteriophage infection efficiency is obtained through combined application of a mycobacterium tuberculosis CRISPR-KO library and a CRISPRi library and bacteriophage D29 infection screening. Reagents or drugs targeting phage susceptibility genes or encoded proteins thereof are screened based on the gene targets, and the reagents or drugs can knock out the phage susceptibility genes or inhibit expression of the phage susceptibility genes, or inhibit activity of the encoded proteins of the phage susceptibility genes, serve as phage synergists, or are combined with antibiotics to be used with phages, and can be used for preparing drugs for treating the phage susceptibility genes or the encoded proteins of the phage susceptibility genes. The bacteriophage-antibiotic composition has the advantages that a synergistic sterilization effect is achieved, a new strategy is provided for bacteriophage-antibiotic combined treatment of drug-resistant mycobacterium infection, rapid sterilization is expected to be achieved, the treatment course is shortened, and finally the target of rapid treatment of tuberculosis and other pathogenic mycobacterium infection is achieved.

The present invention belongs to the technical field of biomedicine, and relates to use of linoleic acid in the preparation of a drug for improving the sensitivity of Gram-positive bacteria to an antibiotic. It has been discovered for the first time that the combined use of linoleic acid and an antibiotic can significantly improve the sensitivity of Gram-positive bacteria to the antibiotic. In vivo study data have shown that the combination of linoleic acid and the antibiotic can not only improve the survival rate of mice infected with Gram-positive bacteria, but also enhance the ability of the mice to clear Gram-positive bacteria. Furthermore, formulating linoleic acid and the antibiotic into an anti-infection composition can, in one aspect, achieve a significant clinical anti-infection effect, and in another aspect, prolong the post-antibiotic effect. Moreover, linoleic acid is an essential fatty acid in human and animal nutrition, with high nutritional value, and it has been widely used in food and pharmaceutical products, demonstrating high safety.

The present invention relates to an antimicrobial composition of a penicillin, a β-lactamase inhibitor and an ion-chelating agent. More particularly, the present invention relates to an antibiotic composition of piperacillin, avibactam and EDTA in a predefined ratio for the effective management of bacterial infections by decreasing the MIC and increasing the stability of the composition.

The invention provides a composition (e.g., pharmaceutical composition) comprising a combination of two or more phages, wherein the phages are two or more of: (a) phage D29; (b) phage AdephagiaΔ41Δ43; (c) phage FionnbharthΔ47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The invention provides a method of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal comprising administering a pharmaceutical composition comprising a combination of two or more phages wherein the phages are two or more of: (a) phage D29; (b) phage AdephagiaΔ41Δ43; (c) phage FionnbharthΔ47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The composition can be administered alone or in combination with one or more antibiotics, wherein the length of treatment is reduced as compared to the length of treatment with one or more antibiotics alone.

The invention belongs to the technical field of biological medicines, and in particular relates to an application of hyssopus rigidus var. Cupidus essential oil in preparation of an antibiotic antibacterial sensitizer and / or preparation of an antibiotic combined medicine, and further relates to an application of the hyssopus rigidus var. Cupidus essential oil in preparation of the antibiotic antibacterial sensitizer and / or the antibiotic combined medicine. It is found that the hyssop officinalis essential oil can enhance the antibacterial sensitivity of various antibiotics including fluconazole and amphotericin B, the hyssop officinalis essential oil and the antibiotics are combined for use, the synergistic antibacterial activity is achieved, and the better antibacterial effect is achieved while the dosage of the antibiotics is reduced; important technical support is provided for improving the current situation of drug resistance of fungi.

The present invention relates to a method, a device for carrying out the method and a kit for quickly determining antibiotic sensitivity and antibiotic resistance by directly measuring bacterial growth in bodily fluids. The present invention relates to the field of health, microbiology, diagnostics and prognosis, and of therapy guidance by evaluating the effectiveness of antibiotics and antibiotic combinations in human and veterinary medicine. The described embodiments relate to determining bacterial growth in samples of bodily fluids ex vivo in the presence of antibiotics added to the samples. The bacterial growth is determined in a device which enables the effectiveness of antibiotics to be immediately monitored in a kit after addition of an aliquot of a bodily fluid in that electric resistance, current flow, impedance or optical measurements are recorded using (fluorescent) dyes, the data are compared with reference values and the data are evaluated by way of programmed calculations and adapted mathematical methods.

The invention belongs to the technical field of biological medicines, and particularly relates to application of linoleic acid in preparation of a medicine for improving sensitivity of gram-positive bacteria to antibiotics. It is found for the first time that combination of linoleic acid and antibiotics can significantly improve the sensitivity of gram-positive bacteria to antibiotics; in-vivo research data shows that the combination of linoleic acid and antibiotics not only can improve the survival rate of mice infected with gram-positive bacteria, but also can improve the ability of mice to remove gram-positive bacteria; linoleic acid and antibiotics are further prepared into the anti-infection composition, on one hand, the remarkable clinical anti-infection effect can be achieved, and on the other hand, the post-effect of the antibiotics can be prolonged; moreover, the linoleic acid is a necessary fatty acid in nutrition of human bodies and animals, is high in nutritional value, is widely applied to food and medicines, and is high in safety.

The application belongs to the technical field of biological medicine, and discloses application of Ebselen as a synergist of polymyxin in inhibition of salmonella. It is found that Ebselen combined with polymyxin has good synergistic effect on salmonella in vitro and in vivo experiments. In a mouse salmonella infection model, the bacterial load in the liver of animals treated with EBS combined with polymyxin is significantly lower than that treated with single drug. The survival rate of animals treated with EBS combined with polymyxin is significantly higher than that treated with EBS and polymyxin alone. Compared with traditional antibiotics and antibiotic combination to kill salmonella, the synergistic bactericidal effect of Ebselen and polymyxin is less likely to induce bacterial drug resistance, and Ebselen has the characteristics of wide source, multiple effects and good treatment effect, which has good research and application significance for exploring antibiotic synergistic replacement and solving bacterial drug resistance.

The present invention relates to a novel bacteriophage OPT-SALO1 with specific killing ability for Salmonella enterica, an antibiotic composition comprising the bacteriophage, a composition for adding to a feed, a feed, a disinfectant or a cleaning agent, and a method for preventing or treating infectious diseases caused by Salmonella enterica comprising a step of administering the bacteriophage to a subject.

This description provides injectable antibiotic compositions for veterinary use. The compositions are characterized by forming a gel at physiological animal temperature, and this gel exhibits a stable and repeatable antibiotic release profile. The compositions comprise a high drug load in poloxamer solutions with the addition of a cosolvent, and preferably with the addition of a cellulose derivative at least partially soluble in organic solvents. Methods for treating veterinary infections are also provided.

An antibiotic composition contains, as an active ingredient, a diatomaceous earth-zinc oxide composite comprising zinc oxide on diatomaceous earth, and an antifungal combination preparation contains a diatomaceous earth-zinc oxide composite including zinc oxide on diatomaceous earth and an antifungal agent. The antibiotic composition is less toxic while exhibiting excellent antibiotic activity, for example, antiviral, antibacterial or antifungal activity. The antibiotic composition is usable to prevent contamination or infection by viruses, bacteria or fungi, inhibit the growth of viruses, bacteria or fungi, or treat infections by viruses, bacteria or fungi.

The present invention discloses a proliferation culture medium for improving in vitro production of urolithin A (Uro-A) by intestinal flora. The culture medium includes brain heart infusion broth (BHI) culture medium, amino acids and antibiotics, wherein the most preferred amino acid combination is L-arginine and L-cysteine, and the most preferred antibiotic combination is chloramphenicol and neomycin sulfate. The present invention can effectively promote the growth and metabolism of urolithin A-producing strains in intestinal flora, greatly improve the yield of urolithin A, and increase 3.02 times compared with the culture medium before optimization. This helps to produce urolithin A by in vitro fermentation of intestinal flora, and the metabolic pathways, product synthesis, enzyme activity and biocatalytic mechanism therein can also be further studied, which has great value for the application in the fields of bioengineering and biopharmaceuticals.

Provided is a use of a combined composition in preparing a drug for resisting fungal and bacterial infections. Active components of the combined composition are an antibiotic and an antibiotic adjuvant, wherein the antibiotic adjuvant is celastrol or a pharmaceutical salt thereof. The present application creatively discovers that celastrol or the pharmaceutical salt thereof can be combined with the antibiotic and the combination has a very excellent effect in resisting the fungal and bacterial infections, especially in resisting the fungal infections. Celastrol or the pharmaceutical salt thereof can enhance an antimicrobial effect of the antibiotic, especially an antifungal effect of the antibiotic, significantly increasing an antimicrobial sensitivity of the antibiotic and inhibiting the occurrence of fungal or bacterial drug-resistance. As an antibiotic adjuvant-antibiotic drug platform, the combined composition provides a new strategy for achieving an efficient antimicrobial effect, and the application dosage forms and the application scenarios are very diverse.

The present invention belongs to the field of biomedicine technology, and specifically relates to a method and a bactericidal composition for effectively reducing the dosage of antibiotics. A method for effectively reducing the dosage of antibiotics, comprising: testing the resistance of pathogens to different antibiotics, determining the initial minimum inhibitory concentration of antibiotics on pathogens; combining bacteriophages with different antibiotics, testing the inhibitory effect of the combination of bacteriophages and antibiotics on pathogens; and determining the minimum inhibitory concentration of the combination of bacteriophages and antibiotics through animal experiments. The method of the present invention, by combining bacteriophages with antibiotics, can significantly prolong the lag period of host pathogens, thereby effectively improving the sensitivity of pathogens to antibiotics. On the premise of ensuring the therapeutic effect, the dosage of antibiotics is greatly reduced, the breeding income is increased, the food quality and safety are improved, and the risk of pathogens developing resistance is reduced. The present invention has significant economic benefits and broad application prospects in the prevention and treatment of poultry farming.

The invention relates to a sepsis diagnosis and treatment scheme recommendation method based on reinforcement learning and clinical knowledge, and the method comprises the steps: firstly modeling an antibiotic combination use problem in a sepsis treatment process into a Markov decision process, and constructing a model through DQN; secondly, deep reinforcement learning based on a value function is combined with sepsis clinical data and medical guideline related content, clinical real data are referred to in a reward function, SOFA scoring knowledge and clinical guideline content are fused, and the model is guided to conduct strategy recommendation in the direction of reasonably shortening antibiotic medication duration and ensuring good prognosis of a patient. According to the constructed model, patient demographic characteristics, basic vital signs, microbial culture results and antibiotic use data serve as model input, four reward functions are constructed in combination with clinical priori knowledge, clinical data and medical guide guidance, the medical interpretability and clinical consistency of SAI-DQN are enhanced, and the method is suitable for clinical application and popularization. And the SAI-DQN is utilized to provide personalized antibiotic combined treatment suggestions for the sepsis patients.

The present invention provides antibiotic combination therapies for treating Acinetobacter baumannii infection in a subject. These combination therapies comprise rifudine and a second antibiotic such as colistin and cefdinir.

Disclosed herein in some aspects are a polysaccharide-coated liposome and a composition comprising the polysaccharide-coated liposome and a pharmaceutically acceptable carrier or excipient. In some embodiments, disclosed herein is a chitosan-coated liposome with lysozyme-responsive properties for on-demand release of an antibiotic encapsulated therein in a lysozyme-rich environment while maintaining the stability of the liposome in a lysozyme-deficient environment.

Described herein are methods preventing or reducing a bacterial infection on a plant seed. In one aspect, the method involves applying to the plant seed epigallocatechin-3 gallate, catechin, epicatechin, or any combination thereof. In one aspect, a mixture comprising epigallocatechin-3 gallate, catechin, and epicatechin is applied to the plant seed. In another aspect, green tea is applied to the plant seed. In other aspects, epigallocatechin-3 gallate, catechin, epicatechin, or any combination thereof is applied to plant seed in combination with an antibiotic, where a synergistic effect is observed. In other aspects, epigallocatechin-3 gallate, catechin, epicatechin, or any combination thereof is added to soil before and / or after the seed is planted in the soil.

The present invention belongs to the technical field of biomedicine, and particularly relates to the application of linoleic acid in the preparation of a medicament for enhancing the antibiotic sensitivity of Gram-positive bacteria. The present invention discovers for the first time that the combination of linoleic acid and an antibiotic can significantly enhance the antibiotic sensitivity of Gram-positive bacteria; in vivo research data shows that the combination of linoleic acid and an antibiotic can not only improve the survival rate of mice infected with Gram-positive bacteria, but also enhance the ability of mice to eliminate Gram-positive bacteria; further, an anti-infective composition prepared from linoleic acid and an antibiotic can, on the one hand, achieve a significant clinical anti-infective effect, and on the other hand, prolong the post-antibiotic effect; moreover, linoleic acid is an essential fatty acid in human and animal nutrition, has high nutritional value, and has been widely used in foods and drugs, with high safety.

The invention belongs to the technical field of biological medicines, and particularly relates to application of linoleic acid in preparation of a medicine for improving sensitivity of gram-positive bacteria to antibiotics. It is found for the first time that combination of linoleic acid and antibiotics can significantly improve the sensitivity of gram-positive bacteria to antibiotics; in-vivo research data shows that the combination of linoleic acid and antibiotics not only can improve the survival rate of mice infected with gram-positive bacteria, but also can improve the ability of mice to remove gram-positive bacteria; linoleic acid and antibiotics are further prepared into the anti-infection composition, on one hand, the remarkable clinical anti-infection effect can be achieved, and on the other hand, the post-effect of the antibiotics can be prolonged; moreover, the linoleic acid is a necessary fatty acid in nutrition of human bodies and animals, is high in nutritional value, is widely applied to food and medicines, and is high in safety.

An antibiotic therapeutic composition or method of treatment includes administering a beta-lactamase inhibitor in combination with a beta-lactam antibiotic. The beta-lactamase inhibitor can be a boronic-acid, a boronic-ester beta-lactamase inhibitor, carboxyl-group beta-lactamase inhibitors, halogen-terminated heterocyclic group beta-lactamase inhibitors, or any pharmaceutically acceptable salts thereof. In combination, the beta-lactamase inhibitors and beta-lactam antibiotics can inhibit the growth of bacteria that are resistant to the beta-lactam antibiotics alone. According to additional embodiments, the effectiveness of various combinations of compounds including various antibiotics and compounds selected from the group consisting of 5-Carboxythiophene-2-boronic acid pinacol ester, 5-Carboxy-2-fluorophenylboronic Acid, 3-Amino-5-carboxylphenylboronic acid, 5-Carboxy-2-chlorophenylboronic acid, 3-Carboxy-2-fluorophenylboronic acid, 5-dehydroxyboryl-2-thiophenecarboxylic acid, and 5-Borono-2-chlorobenzoic acid is demonstrated. Particularly, when combined with certain antibiotics, each of these compounds demonstrates enhanced effectiveness against bacteria and bacterial infections even where the bacteria are known to be resistant to the beta-lactam antibiotics.

The present invention discloses a combination composition of postbiotics and chlorogenic acid and its application, belonging to the technical field of pharmaceutical compositions. The postbiotic composition of the present invention is composed of the postbiotic Postbio YDFF and chlorogenic acid; the postbiotic Postbio YDFF and chlorogenic acid have a synergistic inhibitory effect on the pathogenic microorganism Escherichia coli. In addition, the present invention also provides an antibiotic combination composition, which is composed of the postbiotic Postbio YDFF, chlorogenic acid and antibiotics; the three have a synergistic inhibitory effect on Escherichia coli. The present invention lays a theoretical foundation for the application of postbiotics Postbio YDFF and chlorogenic acid in antibacterial treatment, and provides new ideas and methods for reducing the side effects of drugs and enriching the research and application in the field of antibacterial treatment. At the same time, it also provides a new direction for the screening of drugs for the prevention and treatment of diseases caused by pathogenic bacteria, which is of great significance to the promotion of human health and development.

This disclosure generally relates to small molecule antibiotic and its novel therapeutic uses for treating bacterial infections, alone or in combination with a secondary antibiotic.

The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.

The invention discloses a preparation method of plant protoplast, which is characterized in that the plant protoplast is prepared by using a buffer solution containing mannitol and antibiotic combination, so that the integrity of the protoplast can be increased, and cell pollution can be reduced. The method provided by the invention solves the problems that the active protoplast is directly separated from the plant tissue and the unicellular omics experiment is difficult to carry out, and provides technical support for the research of plants in the aspects of unicellular transcriptomics, genetics, developmental science and the like.

The present invention provides an antibiotic combination therapy for use in the treatment of an Acinetobacter baumannii (A.baumannii) infection in a subject. In particular, these combination therapies include members of antibiotics of the class of rifabutin and polymyxin, such as commercially available natural product antibiotics, e.g., polymyxin B and polymyxin E (colistin and its prodrug colistin mesylate, CMS), as well as synthetic or semi-synthetic derivatives and analogs, e.g., SPR206, MRX-8 and QPX9003, and polymyxin-like antibiotics, e.g., Pol7306.